Cao, Yunlong http://orcid.org/0000-0001-5918-1078
Jian, Fanchong http://orcid.org/0000-0001-8703-3507
Wang, Jing http://orcid.org/0000-0002-9084-9985
Yu, Yuanling
Song, Weiliang
Yisimayi, Ayijiang
Wang, Jing
An, Ran
Chen, Xiaosu
Zhang, Na
Wang, Yao
Wang, Peng
Zhao, Lijuan
Sun, Haiyan
Yu, Lingling
Yang, Sijie
Niu, Xiao
Xiao, Tianhe
Gu, Qingqing http://orcid.org/0000-0001-5805-6419
Shao, Fei
Hao, Xiaohua
Xu, Yanli
Jin, Ronghua http://orcid.org/0000-0001-8496-172X
Shen, Zhongyang http://orcid.org/0000-0003-0045-4355
Wang, Youchun http://orcid.org/0000-0001-9769-5141
Xie, Xiaoliang Sunney http://orcid.org/0000-0001-9281-5239
Article History
Received: 23 September 2022
Accepted: 12 December 2022
First Online: 19 December 2022
Competing interests
: X.S.X. and Y.C. are founders of Singlomics Biopharmaceuticals. Changping Laboratory is in the process of applying for provisional patents (PCT/CN2021/090146 and PCT/CN2021/080537) covering BD series SARS-CoV-2 monoclonal antibodies, including BD-604 (DXP-604), BD55-5840 (SA58) and BD55-5514 (SA55), that lists X.S.X. and Y.C. as inventors. All other authors declare no competing interests.